Compare Aecom (ACM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aecom vs Merck & Co., Inc. — how do they compare? Aecom trades at $68 (market cap $8.69B), while Merck & Co., Inc. trades at $126.15 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 36.6× Aecom's market cap, and Merck & Co., Inc. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| ACM | MRK | |
|---|---|---|
Market Cap | $8.69B | $318.26B |
Sector | Industrials | Health |
52-Week High | $134.35 | $129.52 |
52-Week Low | $66.86 | $77.60 |
Enterprise Value | $10.88B | $361.68B |
Dividend Yield | 1.76% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM trades at $67.64, down 0.15% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.53 and P/S of 0.57, while recent earnings beat expectations in Q1 2026. Analyst consensus is bullish with a $98.83 price target, though recent news includes both contract wins and legal investigations.
The outlook for ACM is mixed: strong valuation metrics and recent contract awards support upside potential, but technical weakness and legal scrutiny pose near-term risks. Earnings growth and margin expansion remain key catalysts, while investor sentiment is cautious due to the stock's 21% decline over the past three months.
Merck (MRK) trades at $125.99, down 0.62% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The stock offers upside to the consensus price target of $139.33, with 68% of analysts rating it a buy. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and potential headwinds from regulatory pressures and patent expirations. Investors should weigh strong cash flow and dividend payments against execution risks in M&A integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
